Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 mai 2018 08h00 HE | Source: MimiVax LLC

MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM Immunotherapy for the Treatment of Newly Diagnosed Glioblastoma

Interim analysis shows significant survival benefit compared to historical standard of care;Combination of SurVaxM and standard therapy was well-tolerated, with few serious side effects;MimiVax to...
15 mai 2018 08h00 HE | Source: MimiVax LLC

MimiVax to Present Interim Phase II Trial Data on Multi-focal Immunotherapy SurVaxM for the Treatment of Glioblastoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

BUFFALO, N.Y., May 15, 2018 (GLOBE NEWSWIRE) -- MimiVax LLC, a clinical-stage biotechnology company developing immunotherapeutics and targeted therapies for cancer treatment, today announced that...